- Home
- MBC vs KYMR Comparison
MBC vs KYMR Comparison
Compare MBC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- KYMR
- Stock Information
- Founded
- MBC 1954
- KYMR 2015
- Country
- MBC United States
- KYMR United States
- Employees
- MBC N/A
- KYMR N/A
- Industry
- MBC Agricultural Chemicals
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- MBC Industrials
- KYMR Health Care
- Exchange
- MBC Nasdaq
- KYMR Nasdaq
- Market Cap
- MBC 2.3B
- KYMR 2.6B
- IPO Year
- MBC N/A
- KYMR 2020
- Fundamental
- Price
- MBC $17.07
- KYMR $40.61
- Analyst Decision
- MBC Strong Buy
- KYMR Buy
- Analyst Count
- MBC 1
- KYMR 15
- Target Price
- MBC $23.00
- KYMR $55.60
- AVG Volume (30 Days)
- MBC 1.3M
- KYMR 532.1K
- Earning Date
- MBC 02-18-2025
- KYMR 02-20-2025
- Dividend Yield
- MBC N/A
- KYMR N/A
- EPS Growth
- MBC N/A
- KYMR N/A
- EPS
- MBC 1.14
- KYMR N/A
- Revenue
- MBC $2,709,800,000.00
- KYMR $87,563,000.00
- Revenue This Year
- MBC $2.41
- KYMR N/A
- Revenue Next Year
- MBC $7.56
- KYMR $33.16
- P/E Ratio
- MBC $14.97
- KYMR N/A
- Revenue Growth
- MBC N/A
- KYMR 86.92
- 52 Week Low
- MBC $13.37
- KYMR $26.92
- 52 Week High
- MBC $20.67
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- MBC 70.11
- KYMR 47.90
- Support Level
- MBC $14.59
- KYMR $40.20
- Resistance Level
- MBC $15.37
- KYMR $44.34
- Average True Range (ATR)
- MBC 0.44
- KYMR 2.58
- MACD
- MBC 0.35
- KYMR 0.29
- Stochastic Oscillator
- MBC 92.52
- KYMR 57.47
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers, and builders.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.